Literature DB >> 11416738

FDG positron emission tomographic, radioiodine, and MIBI imaging in a patient with poorly differentiated insular thyroid carcinoma.

G Zettinig1, T Leitha, B Niederle, K Kaserer, A Becherer, K Kletter, R Dudczak.   

Abstract

Poorly differentiated insular thyroid carcinoma is now classified as a separate entity among other tumors of the thyroid gland. Its histologic pattern and its clinical course are regarded as intermediate between well differentiated and anaplastic thyroid cancer. Insular carcinoma accumulates I-131, but no data exist regarding its fluorodeoxyglucose (FDG) positron emission tomographic (PET) uptake. The authors report F-18 FDG PET, Tc-99m MIBI, and radioiodine imaging features in a 63-year-old patient with metastatic insular thyroid carcinoma. After total thyroidectomy (for poorly differentiated insular carcinoma pT3a), the patient was referred for radioiodine ablation. No signs of recurrence were present until 16 months later, when thyroglobulin levels increased. An I-131 scan showed a single lesion in the right lung, and further radioiodine treatment was administered (cumulative dose [530 mCi], 19,610 MBq I-131). Three years after the initial diagnosis, FDG-PET and Tc-99m MIBI scans were performed within 5 days during thyroxine treatment. After that, thyroxine substitution was withdrawn; 6 weeks later, an I-131 whole-body scan was performed. Both radioiodine and MIBI images showed increased tracer uptake in the known lung lesion. However, FDG PET showed a normal tracer distribution. Magnetic resonance and computed tomographic imaging confirmed a 12-mm lesion in the right upper lobe. These findings support the concept of the "flip-flop phenomenon" in insular thyroid carcinoma, an alternating pattern of metastases with either I-131 or FDG-uptake. Despite poorly differentiated histologic findings, glucose metabolism was not increased in this patient with an insular tumor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11416738     DOI: 10.1097/00003072-200107000-00003

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

1.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

2.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Authors:  Di Wu; Dorina Ylli; Cristiane J Gomes Lima; Wen Lee; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

3.  Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy.

Authors:  Richard Crevenna; Georg Zettinig; Mohammad Keilani; Martin Posch; Manuela Schmidinger; Christian Pirich; Martin Nuhr; Michael Wolzt; Michael Quittan; Veronika Fialka-Moser; Robert Dudczak
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

4.  Insular carcinoma of thyroid: A case report.

Authors:  Rajeev Kumar Kapila; Anita Chaudhary; Samir Sharma; S D Sharma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2006-07

5.  Incidental detection of hyperfunctioning thyroid cancer metastases in patients presenting with thyrotoxicosis.

Authors:  Nishikant A Damle; Chandrasekhar Bal; Praveen Kumar; Ramya Soundararajan; Kiran Subbarao
Journal:  Indian J Endocrinol Metab       Date:  2012-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.